Xilio Therapeutics (XLO) Price to Book (2021 - 2026)

Xilio Therapeutics has disclosed Price to Book across 6 years of filings, most recently posting 2.57 for Q2 2026.

• In Q2 2026, Price to Book fell 72.27% year-over-year to 2.57; the TTM figure through Jun 2026 stood at 2.57 (down 72.27% YoY), while the FY2025 annual figure was 2.12, down 14.46% from the prior year.
• Price to Book came in at 2.57 for Q2 2026 at Xilio Therapeutics, up from 1.9 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 9.28 in Q2 2025 to a low of 15.0 in Q3 2025.
• Average Price to Book over 5 years is 1.13, with a median of 1.17 recorded in 2022.
• Year-over-year, Price to Book jumped 502.24% in 2024 and sank 729.4% in 2025.
• Over 5 years, Price to Book stood at 0.7 in 2022, then tumbled by 40.96% to 0.41 in 2023, then jumped by 502.24% to 2.48 in 2024, then declined by 14.46% to 2.12 in 2025, then advanced by 21.11% to 2.57 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 2.57 in Q2 2026, 1.9 in Q1 2026, and 2.12 in Q4 2025.